We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -15.00 | -0.91% | 1,636.00 | 1,638.00 | 1,639.00 | 1,661.50 | 1,635.50 | 1,656.50 | 4,329,161 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.69 | 67.46B |
From Apr 2022 to Apr 2024
By Michael Susin
GSK PLC said Tuesday that it has started the withdrawal process of the U.S. marketing authorization for its Blenrep treatment, following the request of the country's Food and Drug Administration.
The pharmaceutical giant said the request comes after its Dreamm-3 Phase 3 study in patients with relapsed or refractory multiple myeloma didn't meet its primary endpoint of progression-free survival.
The company said patients treated with Blenrep therapy who have been already enrolled in the risk evaluation and mitigation strategy program will have the option to enroll in a compassionate use program to continue to access treatment.
"We respect the agency's approach to the accelerated approval regulations and associated process," Chief Medical Officer Sabine Luik said. "We will continue the DREAMM clinical trial program and work with the U.S. FDA on a path forward for this important treatment option for patients with multiple myeloma."
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
November 22, 2022 02:51 ET (07:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
